Insights from the society of infectious diseases pharmacists on antimicrobial stewardship guidelines from the infectious diseases society of america and the society for healthcare epidemiology of america

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 593-607

  Drew, Richard H ^a,i   White, Roger ^b,c   MacDougall, Conan ^d   Hermsen, Elizabeth D ^e,f   Owens Jr , Robert C ^g,h  

^a CAMPBELL UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g MAINE MEDICAL CENTER   (United States)

^h UNIVERSITY OF VERMONT   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimicrobial stewardship; Guidelines; Infectious diseases.

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; FLUCONAZOLE; LINEZOLID; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; DRUG MEGADOSE; FEEDBACK SYSTEM; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PRACTICE; HEALTH EDUCATION; HUMAN; INFECTION; INFORMATION TECHNOLOGY; MEDICAL EDUCATION; OUTCOME ASSESSMENT; PHARMACIST; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; REVIEW; WESTERN HEMISPHERE;

ANTI-INFECTIVE AGENTS; CLINICAL AUDIT; COMMUNICABLE DISEASES; EDUCATION, PHARMACY; HEALTH MANPOWER; HEALTH RESOURCES; HUMANS; MEDICAL INFORMATICS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; UNITED STATES;

EID: 66249146905     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.593     Document Type: Review

References (81)

1. . Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-77.
2. . Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988; 157:869-76.
3. . Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-99.
4. . Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433-7.
5. . Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacterspecies. Arch Intern Med 2002;162:185-90.
6. . Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureusbacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
7. . DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327-33.
8. . Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
9. . Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycinresistant Enterococcus faeciumbacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
10. . Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coliand Klebsiella pneumoniaeinfections. Arch Intern Med 2002;162: 2469-77.
11. . Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniaebacteremia: implications of extended-spectrum -lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32.
12. . Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993;104:1230-5.
13. . Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureusin hospitalized patients. Emerg Infect Dis 2003;9:1415-22.
14. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135:175-83.
15. . MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureusand Escherichia coliin 17 US hospitals. Clin Infect Dis 2005;41:435-40.
16. . Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
17. . Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
18. . Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-8.
19. . Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001;33:1462-8.
20. . Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE prevention study group. JAMA 1995;274: 29-34.
21. . Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA 1997;277:312-17.
22. . Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26:299-311.
23. . Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87-93.
24. . Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
25. . Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl 4):S131-8.
26. . MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004;38:284-8.
27. . Fakih MG, Hilu RC, Savoy-Moore RT, Saravolatz LD. Do resident physicians use antibiotics appropriately in treating upper respiratory infections? A survey of 11 programs. Clin Infect Dis 2003;37:853-6.
28. . Metlay JP, Shea JA, Crossette LB, Asch DA. Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med 2002;17: 87-94.
29. . The Joint Commission. Performance measure initiatives. Available from www.jointcommission.org/Performance Measurement/PerformanceMeasurement/. Accessed May 2, 2008.
30. . Centers for Medicare and Medicaid Services. Fact sheet: FY 2008 inpatient prospective payment system final rule. August 1, 2007. Available from www.cms.hhs.gov/apps/media/fact-sheets.asp. Accessed April 7, 2008.
31. . Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP Jr, Prato BS. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med 1997;157: 1689-94.
32. . Gentry CA, Greenfield RA, Slater LN, Wack M, Huycke MM. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm 2000;57:268-74.
33. . Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999;19:1369-77.
34. . Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-48.
35. . McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997;24:57-63.
36. . LaRocco A Jr. Concurrent antibiotic review programs: a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003;37:742-3.
37. . Barlam TF, DiVall M. Antibiotic-stewardship practices at top academic centers throughout the United States and at hospitals throughout Massachusetts. Infect Control Hosp Epidemiol 2006;27:695-703.
38. . Slama T, Band J, Berman S, et al. Position statement from the Infectious Diseases Society of America: hospital pharmacists and infectious diseases specialists. Clin Infect Dis 1997;25:802.
39. . Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis 2004;38:934-8.
40. . Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289-95.
41. . Fishman N. Antimicrobial stewardship. Am J Med 2006; 119:S53-61; discussion S62-70.
42. . MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005;18:638-56.
43. . Owens RC Jr, Fraser GL, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2004;24:896-908.
44. . Parrino TA. Controlled trials to improve antibiotic utilization: a systematic review of experience, 1984-2004. Pharmacotherapy 2005;25:289-98.
45. . Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis 2006;42(suppl 2):S90-5.
46. . Calfee DP, Brooks J, Zirk NM, Giannetta ET, Scheld WM, Farr BM. A pseudo-outbreak of nosocomial infections associated with the introduction of an antibiotic management programme. J Hosp Infect 2003;55:26-32.
47. . Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003;37:180-6.
48. . Belongia EA, Knobloch MJ, Kieke BA, Davis JP, Janette C, Besser RE. Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis 2005;11:912-20.
49. . Girotti MJ, Fodoruk S, Irvine-Meek J, Rotstein OD. Antibiotic handbook and pre-printed perioperative order forms for surgical antibiotic prophylaxis: do they work? Can J Surg 1990;33:385-8.
50. . De Souza V, MacFarlane A, Murphy AW, Hanahoe B, Barber A, Cormican M. A qualitative study of factors influencing antimicrobial prescribing by non-consultant hospital doctors. J Antimicrob Chemother 2006;58:840-3.
51. . Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Shortcourse empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505-11.
52. . Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broadspectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006;10:R78.
53. . Pastel DA, Chang S, Nessim S, Shane R, Morgan MA. Department of pharmacy-initiated program for streamlining empirical antibiotic therapy. Hosp Pharm 1992;27:596-603, 614.
54. . Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ 1995;310:1360-2.
55. . Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic communityacquired Streptococcus pneumoniaepneumonia. Arch Intern Med 2001;161:848-50.
56. . Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-54.
57. . Wong-Beringer A, Nguyen KH, Razeghi J. Implementing a program for switching from I.V. to oral antimicrobial therapy. Am J Health Syst Pharm 2001;58:1146-9.
58. . Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-98.
59. . Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60.
60. . Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg nd/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007;23:2637-45.
61. . Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90.
62. . Drew RH, Kawamoto K, Adams MB. Information technology for optimizing the management of infectious diseases. Am J Health Syst Pharm 2006;63:957-65.
63. . Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS hospital, Salt Lake City. Clin Infect Dis 2001;33(suppl 2):S78-83.
64. . Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother 1999;33:1026-31.
65. . Evans RS, Pestotnik SL, Classen DC, et al. A computerassisted management program for antibiotics and other antiinfective agents. N Engl J Med 1998;338:232-8.
66. . McGregor JC, Weekes E, Forrest GN, et al. Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. J Am Med Inform Assoc 2006;13:378-84.
67. . Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996;124:884-90.
68. . Gruson D, Hilbert G, Vargas F, et al. Strategy of antibiotic rotation: Long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003;31:1908-14.
69. . Hughes MG, Evans HL, Chong TW, et al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the nonintensive care unit ward. Crit Care Med 2004;32:53-60.
70. . Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001;29:1101-8.
71. . Warren DK, Hill HA, Merz LR, et al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobialresistant gram-negative bacteria among intensive care unit patients. Crit Care Med 2004;32:2450-6.
72. . Merz LR, Warren DK, Kollef MH, Fraser VJ. Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Antimicrob Agents Chemother 2004;48:2861-5.
73. . Berild D, Mohseni A, Diep LM, Jensenius M, Ringertz SH. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs. J Antimicrob Chemother 2006;57:326-30.
74. . MacDougall C, Polk RE. Variability in rates of use of antibacterials among 130 US hospitals and risk-adjustment models for interhospital comparison. Infect Control Hosp Epidemiol 2008;29:203-11.
75. . Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 2007;44:867-73.
76. . Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies: what are we missing? Nat Rev Microbiol 2004;2:979-83.
77. . Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003;52:764-71.
78. . Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR, Perencevich EN. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007;45:901-7.
79. . Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45(suppl 2):S112-21.
80. . American College of Clinical Pharmacy. Directory for residencies and fellowships. Available from www.accp.com/ resandfel/directorynon.php. Accessed May 4, 2008.
81. . American Hospital Association. Fast facts on US hospitals. Available from www.aha.org/aha/resource-center/Statistics-and-Studies/fast- facts.html. Accessed May 3, 2008.